SELLAS Life Sciences Group recently reported that its Phase 3 REGAL trial of galinpepimut‑S (GPS) in Acute Myeloid Leukemia had reached 72 of the 80 overall-survival events required for final analysis ...
Good morning, and welcome to the SELLAS Life Sciences R&D Day. As a reminder, this call is being recorded, and a replay will be made available on the SELLAS website following the conclusion of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results